In one of WuXi AppTec’s laboratory buildings, a team of young researchers is finalizing adjustments around a photoreactor. Outside, the chill of early spring lingers, while inside, a specially designed light source brightens a reactor vessel that stands quietly.
At that moment, a client is anxiously awaiting news. They urgently need to synthesize a crucial pharmaceutical intermediate but have encountered a major roadblock at a critical reaction step. After exhausting conventional methods without success, they have turned to WuXi AppTec for assistance.
The wait turns fruitful. The project team utilizes a combination of photochemical reactions and innovative techniques, achieving a scale of over 100 grams within just nine hours, effectively laying the groundwork for further research. Ultimately, the project timeline, initially projected to exceed four months, is dramatically cut to just ten weeks.
When the high-quality product reaches the client, their project lead expresses excitement: “Your mastery and application of photochemistry have opened new doors for optimization, significantly increasing yields and making scale-ups feasible.”
This instance illustrates how WuXi AppTec, over more than two decades, has harnessed its extensive chemistry capabilities within an integrated CRDMO platform to empower both R&D and manufacturing, earning trust from clients.
Innovative Strategies in Photochemistry
The head of the Photochemistry Technology Platform at WuXi AppTec’s Research Chemistry Services emphasizes, “The potential of photochemistry reveals that the boundaries of chemistry can still be expanded. Similar enabling stories unfold every day at WuXi AppTec. By leveraging our comprehensive chemical technologies and capabilities, we can more effectively support clients in overcoming R&D and manufacturing challenges, ultimately helping them deliver innovative therapies to patients faster.”
In the early 2000s, researchers began exploring a new energy source: visible light. In 2008, Professor David MacMillan’s team at Princeton University published groundbreaking work demonstrating that visible light could gently activate chemical bonds to generate previously elusive radicals. Concurrently, research teams at the University of Wisconsin-Madison and the University of Michigan recognized the wider applications of photocatalysis. These studies laid crucial groundwork for modern photoredox catalysis. MacMillan’s later work combined photocatalysis with asymmetric catalysis, allowing for precise control over product structures.
This key discovery opened a new world for synthetic chemists. In 2014, MacMillan partnered with Professor Abigail Doyle to merge photocatalysis with nickel catalysis, effectively tackling the challenge of efficiently constructing C(sp³)-C(sp²) bonds. This breakthrough facilitated the direct use of carboxylic acids in complex drug molecular frameworks, significantly shortening synthetic routes and capturing industry attention.
While photoredox catalysis thrived in academia, it remained an underutilized “test-tube magic trick” in industry—astounding yet challenging to scale.
Recognizing the potential of this innovative technology for drug discovery, WuXi AppTec began strategic investments in photochemistry. In 2016, after thorough preparations, the company established a photocatalysis screening platform, quickly forming a core technical team and offering internal condition screening services.
Overcoming Initial Challenges
The initial phase presented significant challenges. A decade ago, photocatalysis was still emerging in the pharmaceutical industry. “Back then, there weren’t as many light wavelengths, photocatalytic reagents, or photoreactors available. Our first attempt at using photocatalytic reactions for synthetic route design was daunting. However, our team embraced the challenge,” recalled the platform head. “We had to start from scratch, lacking industrial-grade photoreactors and ready-made photocatalysts to screen.”
This young team did not shy away from obstacles. They collaborated with manufacturers to custom-build photoreactors and explored catalysts, ligands, and reaction parameters through extensive experimentation.
Their perseverance paid off. In the first year, the team successfully applied photocatalysis in a project involving a C(sp²)-C(sp³) cross-coupling process, cutting the original four-step route down to two steps, increasing overall yield by over eightfold. Notably, the photochemical approach avoided sensitive reagents and eliminated a potentially hazardous reduction step.
As the team gained experience, their confidence in applying the photocatalytic platform grew. In its second year, a client needed to introduce alkyl groups onto resistant heterocyclic halides. The WuXi AppTec team tackled this through a photocatalytic C(sp³)-C(sp²) decarboxylative coupling strategy. After screening over 30 nickel ligands, they identified a successful photocatalytic method, condensing the original seven-step synthetic route into a single step and reducing the project timeline from two weeks to just four days.
Scaling Up: Bridging the Gap
In the field of photochemical process development, a common saying is, “Getting a photocatalytic reaction to work perfectly in a flask is an art; making it run safely and economically at the kilogram scale in a plant is an entirely different engineering challenge.”
As photocatalysis became operable in high-throughput modes, it evolved from a niche technique to a standard tool for synthetic chemists. However, the challenge of scaling up remained unresolved, presenting an essential step for industrialization.
Following industry trends, WuXi AppTec’s photochemistry team, after focusing on reaction type development and gram-scale synthesis, began addressing this widespread issue. They collaborated with the flow chemistry team to explore methods for scaling up flow photochemistry by effectively integrating high-throughput experimentation (HTE) with flow chemistry.
“HTE can rapidly test hundreds of reaction conditions, quickly identifying optimal formulations; flow chemistry enables stable, batch production of target compounds,” the platform head explained. “It’s akin to developing a new recipe at home for the best combination, then using a central kitchen to validate and solidify the process at larger scales, ultimately delivering a complete, scalable solution to the client.”
Through this collaboration, WuXi AppTec’s chemistry platform continuously expands the types of scalable flow photochemical processes, addressing client needs from hundreds of grams to over a kilogram.
Currently, the company’s photochemistry platform has successfully developed dozens of flow photochemical reaction types and established various scale-up methods. These include challenging deoxygenative coupling reactions, gas-generating cyclopropanations, and hydrazine synthesis involving hazardous reagents.
The Future of Photocatalysis in Drug Development
As photocatalysis technology matures, its application to the synthesis of complex molecules has become increasingly relevant. Take targeted protein degraders (TPDs), a recent focus in drug development. These molecules often feature complex and sensitive structures, posing significant challenges for synthesis and scale-up. Photocatalysis, with its mild and rapid characteristics, is paving new pathways for synthesizing such complex molecules. “Our photochemistry platform has emerged as one of the key technological approaches for synthesizing complex molecules like TPDs,” the platform head stated.
As the technology continues to evolve, the variety of available reaction types expands, and the team becomes more adept at determining effective applications for photocatalysis. This technique not only enhances synthesis efficiency but also allows for transformations that traditional methods struggle to achieve.
Conclusion
WuXi AppTec’s journey from a singular light source in a laboratory to a comprehensive photochemistry platform reflects the company’s commitment to innovation and client support. As more complex molecules are synthesized efficiently under light, the firm not only showcases technical breakthroughs but also reinforces its dedication to clients—delivering greener, more efficient chemistry to illuminate the future of drug development.
- Takeaways:
- WuXi AppTec leverages innovative photochemistry to solve complex synthesis challenges.
- Strategic investments in photochemical technologies have significantly shortened project timelines.
- Collaborations with flow chemistry enhance scalability and efficiency in drug development.
- The company’s comprehensive capabilities build trust and long-term relationships with clients.
- Photocatalysis is becoming a crucial tool in synthesizing complex pharmaceutical molecules.
Read more → news.qq.com